YOUR BUSINESS AUTHORITY

Springfield, MO

Log in Subscribe

Merck inks $11B acquisition

Posted online

Merck announced plans to buy Prometheus Biosciences.

The deal is valued at $10.8 billion.

Prometheus Biosciences has an experimental treatment for ulcerative colitis and Crohn's disease, according to CNBC.

Read more from CNBC.

Comments

No comments on this story |
Please log in to add your comment
Editors' Pick
Transportation officials discuss $471M Forward 44 initiative

Project work in Springfield corridor will continue into 2031.

Most Read
Update cookies preferences